{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:54:44Z","timestamp":1789412084623,"version":"build-2803163510"},"reference-count":229,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejphar.2025.177607","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:02:21Z","timestamp":1744146141000},"page":"177607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Antifibrotic therapeutic strategies in systemic sclerosis: Critical role of the Wnt\/\u03b2-catenin and TGF-\u03b2 signal transduction pathways as potential targets"],"prefix":"10.1016","volume":"999","author":[{"given":"Leyla","family":"Bagheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Javanbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Malekian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh Heshmat","family":"Ghahderijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadra","family":"Taghipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh Davari","family":"Tanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadhosein","family":"Ranjkesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cegolon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177607_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106565","article-title":"Activation of PPAR-\u03b3 induces macrophage polarization and reduces neutrophil migration mediated by heme oxygenase 1","volume":"84","author":"Abdalla","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177607_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol. Int."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177607_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbadis.2017.12.001","article-title":"Inhibition of canonical WNT signaling pathway by \u03b2-catenin\/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12","volume":"1864","author":"Akcora","year":"2018","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/ncomms1734","article-title":"Activation of canonical wnt signaling is required for TGF-beta-mediated fibrosis","volume":"3","author":"Akhmetshina","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.177607_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/ncomms1734","article-title":"Activation of canonical wnt signalling is required for TGF-beta-mediated fibrosis","volume":"3","author":"Akhmetshina","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.177607_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/dth.12248","article-title":"Imatinib treatment of therapy resistant generalized deep morphea","volume":"28","author":"Alcantara-Reifs","year":"2015","journal-title":"Dermatol. Ther."},{"issue":"10","key":"10.1016\/j.ejphar.2025.177607_bib7","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.RES.0000073585.50092.14","article-title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth","volume":"92","author":"Ameshima","year":"2003","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc3419","article-title":"WNT signalling pathways as therapeutic targets in cancer","volume":"13","author":"Anastas","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2025.177607_bib9","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.toxrep.2023.06.006","article-title":"Acute and developmental toxicity of embelin isolated from Embelia schimperi vatke fruit: in vivo and in silico studies","volume":"10","author":"Animaw","year":"2023","journal-title":"Toxicol. Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2133.2012.11199.x","article-title":"Peroxisome proliferator-activated receptor gamma agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts","volume":"168","author":"Antonelli","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/1346-8138.14153","article-title":"Systemic sclerosis","volume":"45","author":"Asano","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fcell.2020.00110","article-title":"Wnt5a signaling in gastric cancer","volume":"8","author":"Astudillo","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7555\/JBR.31.20170034","article-title":"Transforming growth factor-\u03b2 signaling in systemic sclerosis","volume":"32","author":"Ayers","year":"2018","journal-title":"J. Biomed. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177607_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/CS20171426","article-title":"Dual \u03b1v\u03b23 and \u03b1v\u03b25 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis","volume":"132","author":"Bagnato","year":"2018","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejphar.2025.177607_bib15","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1242\/dev.01907","article-title":"The snail genes as inducers of cell movement and survival: implications in development and cancer","volume":"132","author":"Barrallo-Gimeno","year":"2005","journal-title":"Development"},{"issue":"10","key":"10.1016\/j.ejphar.2025.177607_bib16","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1096\/fj.201600502R","article-title":"Wnt\/\u03b2-catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration","volume":"30","author":"Bastakoty","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2025.177607_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0913-x","article-title":"Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study","volume":"18","author":"Bay-Jensen","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejphar.2025.177607_bib18","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.jid.5701101","article-title":"Increased expression of Wnt2 and SFRP4 in tsk mouse skin: role of wnt signaling in altered dermal fibrillin deposition and systemic sclerosis","volume":"128","author":"Bayle","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177607_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejphar.2025.177607_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.intimp.2019.03.061","article-title":"Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib","volume":"72","author":"Bellamri","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177607_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/labinvest.2015.154","article-title":"Canonical wnt signaling in systemic sclerosis","volume":"96","author":"Bergmann","year":"2016","journal-title":"Lab. Invest."},{"issue":"12","key":"10.1016\/j.ejphar.2025.177607_bib22","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1136\/ard.2010.147140","article-title":"Inhibition of glycogen synthase kinase 3\u03b2 induces dermal fibrosis by activation of the canonical wnt pathway","volume":"70","author":"Bergmann","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177607_bib23","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2020-219822","article-title":"X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc)","volume":"80","author":"Bergmann","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib24","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/art.27647","article-title":"Animal models of systemic sclerosis: prospects and limitations","volume":"62","author":"Beyer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2025.177607_bib25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2011-200862","article-title":"Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis","volume":"71","author":"Beyer","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2011-200568","article-title":"\u03b2-Catenin is a central mediator of pro-fibrotic wnt signaling in systemic sclerosis","volume":"71","author":"Beyer","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib27","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2012-202544","article-title":"Blockade of canonical wnt signalling ameliorates experimental dermal fibrosis","volume":"72","author":"Beyer","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177607_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking noncanonical TGFb signalling","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"779","key":"10.1016\/j.ejphar.2025.177607_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abo4974","article-title":"WNT stimulation induces dynamic conformational changes in the frizzled-dishevelled interaction","volume":"16","author":"Bowin","year":"2023","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejphar.2025.177607_bib30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.13238","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"195","author":"Brown","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejphar.2025.177607_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrm3624","article-title":"Talins and kindlins: partners in integrin-mediated adhesion","volume":"14","author":"Calderwood","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177607_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019809","article-title":"Wnt3a induces myofibroblast differentiation by upregulating TGF-Beta signaling through SMAD2 in a beta-catenin-dependent manner","volume":"6","author":"Carthy","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ejphar.2025.177607_bib33","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.it.2018.08.006","article-title":"Canonical and non-canonical wnt signaling in immune cells","volume":"39","author":"Chae","year":"2018","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177607_bib34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.21725","article-title":"Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts","volume":"54","author":"Chen","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"22","key":"10.1016\/j.ejphar.2025.177607_bib35","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.3390\/ijms20225552","article-title":"Wnt signaling and biological therapy in rheumatoid arthritis and spondyloarthritis","volume":"20","author":"Cici","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.177607_bib36","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3899\/jrheum.150088","article-title":"The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-beta and May be blocked by macitentan, a dual endothelin-1 receptor antagonist","volume":"42","author":"Cipriani","year":"2015","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177607_bib37","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/Beta-Catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.177607_bib38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2019.08.015","article-title":"Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis","volume":"310","author":"Codullo","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2025.177607_bib39","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015081","article-title":"Secreted and transmembrane wnt inhibitors and activators","volume":"5","author":"Cruciat","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2025.177607_bib40","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177607_bib41","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1681\/ASN.2009010019","article-title":"Wnt\/Beta-Catenin signaling promotes podocyte dysfunction and albuminuria","volume":"20","author":"Dai","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177607_bib42","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-Beta and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.177607_bib43","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/124624","article-title":"The role of PPAR gamma in systemic sclerosis","volume":"2015","author":"Dantas","year":"2015","journal-title":"PPAR Res."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib44","article-title":"Reassessing the role of the active TGF\u2010\u03b21 as a biomarker in systemic sclerosis: association of serum levels with clinical manifestations","volume":"2016","author":"Dantas","year":"2016","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ejphar.2025.177607_bib45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10787-023-01296-9","article-title":"PPAR\u03b3 partial agonist LPSF\/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients","volume":"32","author":"De Almeida","year":"2024","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejphar.2025.177607_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12931-021-01863-0","article-title":"Dual inhibition of \u03b1v\u03b26 and \u03b1v\u03b21 reduces fibrogenesis in lung tissue explants from patients with IPF","volume":"22","author":"Decaris","year":"2021","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177607_bib47","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/rheumatology\/keab580","article-title":"Transcriptome analysis reveals key genes modulated by ALK5 inhibition in a bleomycin model of systemic sclerosis","volume":"61","author":"Decato","year":"2022","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.ejphar.2025.177607_bib48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/exd.12255","article-title":"Canonical wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies?","volume":"22","author":"Dees","year":"2013","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib49","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/annrheumdis-2012-203194","article-title":"The wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis","volume":"73","author":"Dees","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib50","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","article-title":"Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies","volume":"74","author":"Dees","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib51","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177607_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177607_bib53","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib54","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13075-021-02592-x","article-title":"The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis","volume":"23","author":"Derrett-Smith","year":"2021","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177607_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22950","article-title":"Embelin: a novel XIAP inhibitor for the prevention and treatment of chronic diseases","volume":"36","author":"Devi Daimary","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.ejphar.2025.177607_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/cei.13599","article-title":"Endothelial-to-mesenchymal transition in systemic sclerosis","volume":"205","author":"Di Benedetto","year":"2021","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2025.177607_bib58","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2012-202275","article-title":"Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical wnt signaling","volume":"72","author":"Distler","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"26","key":"10.1016\/j.ejphar.2025.177607_bib59","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177607_bib60","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2665-9913(23)00238-2","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial","volume":"5","author":"Distler","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"10.1016\/j.ejphar.2025.177607_bib61","first-page":"1518","article-title":"Circulating levels of active transforming growth factor \u03b21 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified rodnan skin score, rheumatology","volume":"44","author":"Dziadzio","year":"2005"},{"key":"10.1016\/j.ejphar.2025.177607_bib62","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00109-014-1190-x","article-title":"Molecular and cellular basis of scleroderma","volume":"92","author":"Eckes","year":"2014","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ejphar.2025.177607_bib63","doi-asserted-by":"crossref","unstructured":"Enzo, M.V., Rastrelli, M., Rossi, C.R. et al. The Wnt\/\u03b2-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target. Mol. Cell Ther. 2015 30;3:1. https:\/\/doi.org\/10.1186\/s40591-015-0038-2.","DOI":"10.1186\/s40591-015-0038-2"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177607_bib64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.molcel.2017.06.009","article-title":"Wnt-dependent inactivation of the Groucho\/TLE co-repressor by the HECT E3 ubiquitin ligase Hyd\/UBR5","volume":"67","author":"Flack","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2025.177607_bib65","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177607_bib66","doi-asserted-by":"crossref","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib67","doi-asserted-by":"crossref","DOI":"10.1186\/2045-3701-4-13","article-title":"Regulation of wnt\/Beta-Catenin signaling by posttranslational modifications","volume":"4","author":"Gao","year":"2014","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ejphar.2025.177607_bib68","article-title":"Osteopontin links myeloid activation and disease progression in systemic sclerosis","volume":"1","author":"Gao","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejphar.2025.177607_bib69","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/kep189","article-title":"Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts","volume":"48","author":"Garcia-Gonzalez","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejphar.2025.177607_bib70","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bcp.2019.02.029","article-title":"Cannabinoid derivatives acting as dual PPAR\u03b3\/CB2 agonists as therapeutic agents for systemic sclerosis","volume":"163","author":"Garc\u00eda-Mart\u00edn","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177607_bib71","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/annrheumdis-2021-220209","article-title":"Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis","volume":"80","author":"Gaydosik","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib72","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature12614","article-title":"Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma","volume":"503","author":"Gerber","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejphar.2025.177607_bib73","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177607_bib74","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"6 Suppl. 86","key":"10.1016\/j.ejphar.2025.177607_bib75","article-title":"Imatinib mesylate (gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial","volume":"32","author":"Gordon","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib76","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1101\/gad.1957710","article-title":"Canonical and noncanonical wnts use a common mechanism to activate completely unrelated coreceptors","volume":"24","author":"Grumolato","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejphar.2025.177607_bib77","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.yjmcc.2017.07.011","article-title":"Entanglement of GSK-3beta, beta-catenin and TGF-beta1 signaling network to regulate myocardial fibrosis","volume":"110","author":"Guo","year":"2017","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2025.177607_bib78","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1038\/jid.2012.155","article-title":"Sustained beta-catenin activity in dermal fibroblasts is sufficient for skin fibrosis","volume":"132","author":"Hamburg","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib79","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1681\/ASN.2010101079","article-title":"Targeted inhibition of beta-catenin\/CBP signaling ameliorates renal interstitial fibrosis","volume":"22","author":"Hao","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177607_bib80","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nature11019","article-title":"ZNRF3 promotes wnt receptor turnover in an R-spondin-sensitive manner","volume":"485","author":"Hao","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ejphar.2025.177607_bib81","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1242\/dev.01117","article-title":"LDL receptor-related proteins 5 and 6 in Wnt\/\u03b2-catenin signaling: arrows point the way","volume":"131","author":"He","year":"2004","journal-title":"Development"},{"key":"10.1016\/j.ejphar.2025.177607_bib82","doi-asserted-by":"crossref","first-page":"14309","DOI":"10.1073\/pnas.1001520107","article-title":"Inhibition of Wnt\/beta-catenin\/CREB binding protein (CBP) signaling reverses pulmonary fibrosis","volume":"107","author":"Henderson","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejphar.2025.177607_bib83","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177607_bib84","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molmed.2019.02.001","article-title":"The role of epigenetic modifications in systemic sclerosis: a druggable target","volume":"25","author":"Henderson","year":"2019","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib85","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/exd.14136","article-title":"Wnt antagonist DKK-1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a-3p","volume":"30","author":"Henderson","year":"2021","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib86","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/ker442","article-title":"Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease","volume":"51","author":"Hesselstrand","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejphar.2025.177607_bib87","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejphar.2025.177607_bib88","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s12032-010-9601-5","article-title":"Embelin induces 267 apoptosis through down-regulation of XIAP in human leukemia cells","volume":"28 268","author":"Hu","year":"2011","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177607_bib230","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/1440-1681.13270","article-title":"WNT\/\u03b2-catenin signal inhibitor IC-2-derived small-molecule compounds suppress TGF-\u03b21-induced fibrogenic response of renal epithelial cells by inhibiting SMAD2\/3 signalling","volume":"47","author":"Hoi","year":"2020","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.ejphar.2025.177607_bib89","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41413-024-00342-8","article-title":"Wnt\/\u03b2-catenin signaling components and mechanisms in bone formation, homeostasis, and disease","volume":"12","author":"Hu","year":"2024","journal-title":"Bone Res."},{"issue":"36","key":"10.1016\/j.ejphar.2025.177607_bib90","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.3748\/wjg.v24.i36.4178","article-title":"Mechanism of combined use of vitamin D and puerarin in anti-hepatic fibrosis by regulating the Wnt\/\u03b2-catenin signalling pathway","volume":"24","author":"Huang","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2025.177607_bib91","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nature08356","article-title":"Tankyrase inhibition stabilizes axin and antagonizes wnt signaling","volume":"461","author":"Huang","year":"2009","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.ejphar.2025.177607_bib92","doi-asserted-by":"crossref","first-page":"22098e113","DOI":"10.18632\/oncotarget.4300","article-title":"Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120)","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.177607_bib93","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2014-207109","article-title":"Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis","volume":"75","author":"Huang","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177607_bib94","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.resinv.2020.01.003","article-title":"Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-\u03b2\/Smad pathway","volume":"58","author":"Ihara","year":"2020","journal-title":"Respirat. Invest."},{"key":"10.1016\/j.ejphar.2025.177607_bib95","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-3565(24)35110-9","article-title":"Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"291","author":"Iyer","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2025.177607_bib96","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1023\/A:1007068313370","article-title":"Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation","volume":"24","author":"Iyer","year":"2000","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tem.2012.10.003","article-title":"LRP5 and LRP6 in development and disease","volume":"24","author":"Joiner","year":"2013","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejphar.2025.177607_bib98","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd4233","article-title":"Can we safely target the WNT pathway?","volume":"13","author":"Kahn","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.177607_bib99","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jdermsci.2018.02.001","article-title":"Pro-fibrotic phenotype of human skin fibroblasts induced by periostin via modulating TGF-Beta signaling","volume":"90","author":"Kanaoka","year":"2018","journal-title":"J. Dermatol. Sci."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177607_bib100","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2005-02-0695","article-title":"Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis","volume":"106","author":"Kater","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.177607_bib101","article-title":"Blocking TGF\u03b2 via inhibition of the \u03b1v\u03b26 integrin: a possible therapy for systemic sclerosis interstitial lung disease","volume":"2011","author":"Katsumoto","year":"2011","journal-title":"Internet J. Rheumatol."},{"issue":"13","key":"10.1016\/j.ejphar.2025.177607_bib102","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1242\/jcs.00623","article-title":"Secreted antagonists of the wnt signalling pathway","volume":"116","author":"Kawano","year":"2003","journal-title":"J. Cell Sci."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177607_bib103","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib104","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib105","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/art.30548","article-title":"A one-year, phase I\/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177607_bib106","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"(a) an open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib107","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"(C) safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"10038","key":"10.1016\/j.ejphar.2025.177607_bib108","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"(b). Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177607_bib109","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"focussed investigators (a). Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177607_bib110","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3899\/jrheum.191365","article-title":"STRATUS: a phase II study of abituzumab in patients with systemic sclerosis-associated interstitial lung disease","volume":"48","author":"Khanna","year":"2021","journal-title":"J. Rheumatol."},{"issue":"17","key":"10.1016\/j.ejphar.2025.177607_bib111","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib blocks IFN-Regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejphar.2025.177607_bib112","first-page":"74","article-title":"Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the scleroderma lung study III","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib113","article-title":"Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis","volume":"9","author":"Khanna","year":"2024","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.ejphar.2025.177607_bib114","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/1756-185X.13973","article-title":"Relationship of wnt pathway activity and organ involvement in scleroderma types","volume":"23","author":"Ko\u00e7ak","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopha.2005.04.004","article-title":"Inhibition of skin sclerosis by 15deoxy delta12,14-prostaglandin J2 and retrovirally transfected prostaglandin D synthase in a mouse model of bleomycin-induced scleroderma","volume":"60","author":"Kohno","year":"2006","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177607_bib116","doi-asserted-by":"crossref","first-page":"64","DOI":"10.7812\/TPP\/09-052","article-title":"Thiazolidinediones: a 2010 perspective","volume":"14","author":"Krishnaswami","year":"2010","journal-title":"Perm. J."},{"key":"10.1016\/j.ejphar.2025.177607_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015909","article-title":"PPAR-Gamma ligands repress TGFbeta-induced myofibroblast differentiation by targeting the pi3k\/akt pathway: implications for therapy of fibrosis","volume":"6","author":"Kulkarni","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ejphar.2025.177607_bib118","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.jid.2017.06.032","article-title":"Inhibition of \u03b2-Catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double-blind, placebo-controlled trial of C-82","volume":"137","author":"Lafyatis","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib119","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/annrheumdis-2020-eular.1753","article-title":"Safety, target engagement, and initial efficacy of Avid200, a first-in-class potent and isoform-selective inhibitor of tgf-beta 1 and 3, in patients with diffuse cutaneous systemic sclerosis (dcssc): a phase 1 dose escalation study","volume":"79","author":"Lafyatis","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib120","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1042\/BCJ20160943","article-title":"Transforming growth factor beta suppresses peroxisome proliferator-activated receptor gamma expression via both smad binding and novel TGF-Beta inhibitory elements","volume":"474","author":"Lakshmi","year":"2017","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2025.177607_bib121","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrrheum.2013.94","article-title":"Connective tissue diseases: epigenetic silencing of wnt inhibition in systemic sclerosis","volume":"9","author":"Leah","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib122","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1096\/fj.03-1273rev","article-title":"TGF-Beta signaling and the fibrotic response","volume":"18","author":"Leask","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2025.177607_bib123","doi-asserted-by":"crossref","first-page":"F1263","DOI":"10.1152\/ajprenal.00475.2009","article-title":"Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K\/Akt, GSK-3beta, Snail1, and beta-catenin in renal proximal tubule cells","volume":"298","author":"Lee","year":"2010","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2025.177607_bib124","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1124\/mol.106.022954","article-title":"Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-Mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation","volume":"70","author":"Lee","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177607_bib125","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fphar.2017.00174","article-title":"Deficient adipogenesis of scleroderma patient and healthy African American monocytes","volume":"8","author":"Lee","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177607_bib126","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbrc.2015.05.020","article-title":"Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3beta signaling pathway","volume":"463","author":"Liang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177607_bib127","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/annrheumdis-2016-209698","article-title":"The transcription factor GLI2 as a downstream mediator of transforming growth factor-beta-induced fibroblast activation in SSc","volume":"76","author":"Liang","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/Beta-Catenin signaling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.177607_bib130","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1111\/ajt.12467","article-title":"Inhibition of \u03b1v\u03b26 promotes acute renal allograft rejection in nonhuman Primates","volume":"13","author":"Lo","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ejphar.2025.177607_bib131","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10238-022-00841-0","article-title":"Transforming growth factor beta isoforms and TGF-\u03b2R1 and TGF-\u03b2R2 expression in systemic sclerosis patients","volume":"23","author":"Lomel\u00ed-Nieto","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ejphar.2025.177607_bib132","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cell.2004.09.019","article-title":"Mammalian ryk is a wnt coreceptor required for stimulation of neurite outgrowth","volume":"119","author":"Lu","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.177607_bib133","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12931-016-0373-0","article-title":"Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung","volume":"17","author":"Lucattelli","year":"2016","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177607_bib134","first-page":"595","article-title":"MicroRNA-130b regulates Scleroderma fibrosis by targeting peroxisome proliferator-activated receptor g","volume":"25","author":"Luo","year":"2015"},{"key":"10.1016\/j.ejphar.2025.177607_bib135","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/art.24435","article-title":"Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes","volume":"60","author":"Luzina","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2025.177607_bib136","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3389\/fimmu.2016.00378","article-title":"Crosstalk between Wnt\/\u03b2-catenin and NF-\u03baB signaling pathway during inflammation","volume":"7","author":"Ma","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2025.177607_bib137","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007880","article-title":"Frizzled and LRP5\/6 receptors for wnt\/Beta-Catenin signaling","volume":"4","author":"MacDonald","year":"2012","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2025.177607_bib138","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1755-1536-3-16","article-title":"The multifaceted role of pirfenidone and its novel targets","volume":"3","author":"Mac\u00edas-Barrag\u00e1n","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib139","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12931-020-01339-7","article-title":"A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled \u03b1v\u03b26 integrin inhibitor","volume":"21","author":"Maher","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejphar.2025.177607_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115905","article-title":"Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGF\u03b2 pathway inhibition","volume":"438","author":"Maher","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177607_bib141","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/sj.emboj.7601689","article-title":"Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1","volume":"26","author":"Maiuri","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2025.177607_bib142","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.760776","article-title":"Longitudinal and comparative measures of serum chitotriosidase and YKL-40 in patients with idiopathic pulmonary fibrosis","volume":"13","author":"Majewski","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2025.177607_bib143","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/art.38990","article-title":"Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors","volume":"67","author":"Marangoni","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177607_bib144","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1080\/1744666X.2020.1670062","article-title":"Biomarkers of skin and lung fibrosis in systemic sclerosis","volume":"15","author":"Martinovic Kaliterna","year":"2019","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"10","key":"10.1016\/j.ejphar.2025.177607_bib145","first-page":"616","article-title":"TGF\u03b2 signalling in context","volume":"13","author":"Massagu\u00e9","year":"2012"},{"key":"10.1016\/j.ejphar.2025.177607_bib146","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jid.2016.01.036","article-title":"beta-catenin stabilization in skin fibroblasts causes fibrotic lesions by preventing adipocyte differentiation of the reticular dermis","volume":"136","author":"Mastrogiannaki","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib147","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.trsl.2021.01.001","article-title":"Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition","volume":"231","author":"Mendoza","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejphar.2025.177607_bib148","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nrm3906","article-title":"Extracellular matrix: preconditioning the ECM for fibrosis","volume":"15","author":"Minton","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.177607_bib149","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/j.jaad.2010.02.030","article-title":"Imatinib treatment of generalized localized Scleroderma (morphea)","volume":"63","author":"Moinzadeh","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib150","article-title":"Bexotegrast shows dose-dependent integrin \u03b1v\u03b26 receptor occupancy in lungs of participants with idiopathic pulmonary fibrosis: a phase 2, open-label clinical trial","volume":"5","author":"Mooney","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.ejphar.2025.177607_bib151","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/art.11157","article-title":"Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts","volume":"48","author":"Mori","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2025.177607_bib152","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/kez532","article-title":"The clinical and economic burden of systemic sclerosis related interstitial lung disease","volume":"59","author":"Morrisroe","year":"2020","journal-title":"Rheumatology"},{"issue":"1e3","key":"10.1016\/j.ejphar.2025.177607_bib153","article-title":"A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-a at the translational level","volume":"446","author":"Nakazato","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177607_bib154","article-title":"Vascular remodelling and mesenchymal transition in systemic sclerosis","volume":"2016","author":"Nicolosi","year":"2016","journal-title":"Stem Cell. Int."},{"key":"10.1016\/j.ejphar.2025.177607_bib155","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/art.42063","article-title":"Involvement of multiple variants of soluble CD146 in systemic sclerosis: identification of a novel profibrotic factor","volume":"74","author":"Nollet","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib156","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1101\/cshperspect.a011163","article-title":"Wnt signaling","volume":"4","author":"Nusse","year":"2012","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2025.177607_bib157","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177607_bib158","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mam.2016.10.001","article-title":"Epigenetics in fibrosis","volume":"54","author":"O'Reilly","year":"2017","journal-title":"Mol. Aspect. Med."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177607_bib159","article-title":"Evolution of the TGF-\u03b2 signaling pathway and its potential role in the ctenophore","volume":"6","author":"Pang","year":"2011","journal-title":"Mnemiopsis leidyi[J]"},{"issue":"8","key":"10.1016\/j.ejphar.2025.177607_bib160","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/art.23698","article-title":"Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate","volume":"58","author":"Pannu","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177607_bib161","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/biomedicines10020316","article-title":"Therapeutic options for systemic sclerosis: current and future perspectives in tackling immune-mediated fibrosis","volume":"10","author":"Papadimitriou","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.177607_bib162","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2025.177607_bib163","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.abb.2011.12.019","article-title":"The many roles of PTK7: a versatile regulator of cell-cell communication","volume":"524","author":"Peradziryi","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib164","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/art.38897","article-title":"Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis","volume":"67","author":"Ponticos","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177607_bib165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/13543784.2014.867016","article-title":"Embelin \u2013 a drug of antiquity: shifting the paradigm towards modern medicine","volume":"23","author":"Poojari","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.ejphar.2025.177607_bib166","first-page":"1015","article-title":"Chemopreventive and hepatoprotective effects of embelin on N-nitrosodiethylamine and carbon tetrachloride induced preneoplasia and toxicity in rat liver","volume":"11","author":"Poojari","year":"2010","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.ejphar.2025.177607_bib167","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30010-2","article-title":"The future of treatment in systemic sclerosis: can we design better trials?","volume":"2","author":"Pope","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.ejphar.2025.177607_bib168","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1164\/rccm.202112-2824OC","article-title":"A phase IIb randomized clinical study of an Anti-\u03b1v\u03b26 monoclonal antibody in idiopathic pulmonary fibrosis","volume":"206","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177607_bib169","first-page":"593","article-title":"TGF-Beta signaling: a tale of two responses","volume":"102","author":"Rahimi","year":"2007"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/rcmb.2014-0445OC","article-title":"Novel mechanisms for the antifibrotic action of nintedanib","volume":"54","author":"Rangarajan","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177607_bib171","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1073\/pnas.1211179110","article-title":"LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1","volume":"110","author":"Ren","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2025.177607_bib172","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1158\/1541-7786.MCR-10-0141","article-title":"Embelin 302 suppresses osteoclastogenesis induced by receptor activator of NF-\u03baB ligand and tumor 303 cells in vitro through inhibition of the NF-\u03baB cell signaling pathway","volume":"8","author":"Reuter","year":"2010","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177607_bib173","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.177607_bib174","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177607_bib175","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.ejphar.2025.177607_bib176","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Allanore. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib177","series-title":"Reactive Oxygen Species","article-title":"Soluble guanylate cyclase stimulators and activators","volume":"vol. 264","author":"Sandner","year":"2018"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177607_bib178","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"J. Dermatol. Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177607_bib179","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2249.2004.02642.x","article-title":"Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement","volume":"138","author":"Scala","year":"2004","journal-title":"Clin. Exp. Immunol."},{"issue":"120","key":"10.1016\/j.ejphar.2025.177607_bib180","doi-asserted-by":"crossref","first-page":"85e97","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur. Respir. Rev."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177607_bib181","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41581-020-00343-w","article-title":"WNT-beta-catenin signaling - a versatile player in kidney injury and repair","volume":"17","author":"Schunk","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177607_bib182","article-title":"Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis. Clin","volume":"254","author":"Sheng","year":"2023","journal-title":"Immunol. Ser."},{"key":"10.1016\/j.ejphar.2025.177607_bib183","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0790","article-title":"Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis","volume":"11","author":"Shin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2025.177607_bib184","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.177607_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116130","article-title":"The involvement of the Wnt\/\u03b2-catenin signaling Cascade in fibrosis progression and its therapeutic targeting by relaxin","volume":"223","author":"Somanader","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177607_bib186","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2025.177607_bib187","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of lenabasum in a phase ii, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177607_bib188","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.42510","article-title":"Efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous systemic sclerosis","volume":"75","author":"Spiera","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib189","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007898","article-title":"The beta-catenin destruction complex","volume":"5","author":"Stamos","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2025.177607_bib190","doi-asserted-by":"crossref","DOI":"10.1242\/dev.146589","article-title":"Wnt signaling in development and tissue homeostasis","volume":"145","author":"Steinhart","year":"2018","journal-title":"Development"},{"key":"10.1016\/j.ejphar.2025.177607_bib191","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41556-018-0234-9","article-title":"Integrin activation by talin, kindlin and mechanical forces","volume":"21","author":"Sun","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.177607_bib192","doi-asserted-by":"crossref","first-page":"eabe0407","DOI":"10.1126\/scitranslmed.abe0407","article-title":"TGFbeta2 and TGFbeta3 isoforms drive fibrotic disease pathogenesis","volume":"13","author":"Sun","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177607_bib193","first-page":"132","article-title":"Isoform-selective TGF-\u03b23 inhibition for systemic sclerosis","volume":"5","author":"Sun","year":"2024","journal-title":"M\u00e9d. Sur"},{"key":"10.1016\/j.ejphar.2025.177607_bib194","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1128\/MCB.00586-15","article-title":"SIRT3 blocks aging-associated tissue fibrosis in mice by deacetylating and activating glycogen synthase kinase 3beta","volume":"36","author":"Sundaresan","year":"2015","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.177607_bib195","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004592","article-title":"Oxidative DNA damage induces the ATM-Mediated transcriptional suppression of the wnt inhibitor WIF-1 in systemic sclerosis and fibrosis","volume":"7","author":"Svegliati","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejphar.2025.177607_bib196","series-title":"Cancer Management: a Multidisciplinary Approach","first-page":"11","article-title":"Principles of oncologic pharmacotherapy\"","author":"Takimoto","year":"2008"},{"key":"10.1016\/j.ejphar.2025.177607_bib197","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/35035117","article-title":"LDL-receptor-related proteins in wnt signal transduction","volume":"407","author":"Tamai","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.177607_bib198","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/exd.13724","article-title":"CXCL13 produced by macrophages due to Fli1 deficiency May contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis","volume":"27","author":"Taniguchi","year":"2018","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib199","first-page":"L22","article-title":"Transforming growth factor-\u03b2 plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma","volume":"312","author":"Tsujino","year":"2017"},{"issue":"21","key":"10.1016\/j.ejphar.2025.177607_bib200","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1158\/0008-5472.CAN-04-1013","article-title":"SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo","volume":"64","author":"Uhl","year":"2004","journal-title":"Cancer Res."},{"issue":"52","key":"10.1016\/j.ejphar.2025.177607_bib201","doi-asserted-by":"crossref","first-page":"90579","DOI":"10.18632\/oncotarget.21234","article-title":"Interactions between TGF-\u03b21, canonical WNT\/\u03b2-catenin pathway and PPAR \u03b3 in radiation-induced fibrosis","volume":"8","author":"Vall\u00e9e","year":"2017","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.ejphar.2025.177607_bib202","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1111\/bph.13922","article-title":"Molecular regulation and pharmacological targeting of the beta-catenin destruction complex","volume":"174","author":"van Kappel","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177607_bib203","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2741\/s22","article-title":"Transforming growth factor-beta in systemic sclerosis (scleroderma)","volume":"1","author":"Varga","year":"2009","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejphar.2025.177607_bib204","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J. Scleroderma Relat. Disord."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177607_bib205","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-014-0037-0","article-title":"Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels","volume":"34","author":"Vettori","year":"2014","journal-title":"J. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177607_bib206","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00018-019-03221-2","article-title":"Src and fyn define a new signaling Cascade activated by canonical and non-canonical wnt ligands and required for gene transcription and cell invasion","volume":"77","author":"Villarroel","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"10373","key":"10.1016\/j.ejphar.2025.177607_bib207","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177607_bib208","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2174\/138161213804581837","article-title":"Wnt\/Beta-Catenin signaling and small molecule inhibitors","volume":"19","author":"Voronkov","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib209","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.04-2370com","article-title":"Imatinib mesylate blocks a non-Smad TGF-Beta pathway and reduces renal fibrogenesis in vivo","volume":"19","author":"Wang","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2025.177607_bib210","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3892\/ol.2012.713","article-title":"Methylation and aberrant expression of the wnt antagonist secreted Frizzled-related protein 1 in bladder cancer","volume":"4","author":"Wang","year":"2012","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177607_bib211","doi-asserted-by":"crossref","first-page":"C234","DOI":"10.1152\/ajpcell.00366.2013","article-title":"Inhibition of wnt\/Beta-Catenin signaling promotes epithelial differentiation of mesenchymal stem cells and repairs bleomycin-induced lung injury","volume":"307","author":"Wang","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2025.177607_bib212","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/BOR.0b013e32833de1a7","article-title":"Peroxisome proliferator-activated receptor \u03b3: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis","volume":"22","author":"Wei","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.ejphar.2025.177607_bib213","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/art.30312","article-title":"Canonical wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?","volume":"63","author":"Wei","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177607_bib214","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/art.34424","article-title":"Wnt\/\u03b2-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells","volume":"64","author":"Wei","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177607_bib215","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/annrheumdis-2012-202716","article-title":"A synthetic PPAR-Gamma agonist triterpenoid ameliorates experimental fibrosis: ppar-gamma-independent suppression of fibrotic responses","volume":"73","author":"Wei","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177607_bib216","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2353\/ajpath.2009.080574","article-title":"Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma","volume":"174","author":"Wu","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177607_bib217","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1756-185X.13247","article-title":"Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease","volume":"21","author":"Xiao","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177607_bib218","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jcmm.13085","article-title":"Activation of wnt\/Beta-Catenin signaling is required for TGF-beta\/Smad2\/3 signaling during myofibroblast proliferation","volume":"21","author":"Xu","year":"2017","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2025.177607_bib219","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41413-017-0005-4","article-title":"Transforming growth factor-beta in stem cells and tissue homeostasis","volume":"6","author":"Xu","year":"2018","journal-title":"Bone Res."},{"key":"10.1016\/j.ejphar.2025.177607_bib220","article-title":"Integrin activating molecule-talin1 promotes skin fibrosis in systemic sclerosis","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177607_bib221","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1038\/s41467-018-05768-3","article-title":"The tyrosine phosphatase SHP2 controls TGFbeta-induced STAT3 signaling to regulate fibroblast activation and fibrosis","volume":"9","author":"Zehender","year":"2018","journal-title":"Nat. Commun."},{"issue":"10.1016","key":"10.1016\/j.ejphar.2025.177607_bib222","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yexcr.2015.08.014","article-title":"Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells","volume":"338","author":"Zenzmaier","year":"2015","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejphar.2025.177607_bib223","first-page":"2740","article-title":"Pioglitazone increases VEGFR3 expression and promotes activation of M2 macrophages via the peroxisome proliferator-activated receptor \u03b3","volume":"19","author":"Zhang","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"17","key":"10.1016\/j.ejphar.2025.177607_bib224","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/blood.2020008720","article-title":"Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease","volume":"137","author":"Zhang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.177607_bib225","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","article-title":"Targeting fibrosis: mechanisms and clinical trials","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"25","key":"10.1016\/j.ejphar.2025.177607_bib226","doi-asserted-by":"crossref","first-page":"11737","DOI":"10.7150\/thno.47717","article-title":"Glycogen synthase kinase-3\u03b2: a promising candidate in the fight against fibrosis","volume":"10","author":"Zheng","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2025.177607_bib227","first-page":"412","article-title":"MicroRNA-202-3p regulates Scleroderma fibrosis by targeting matrix metalloproteinase 1","volume":"87","author":"Zhou","year":"2017"},{"issue":"3","key":"10.1016\/j.ejphar.2025.177607_bib228","first-page":"514","article-title":"MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma","volume":"32","author":"Zhu","year":"2012"},{"issue":"6","key":"10.1016\/j.ejphar.2025.177607_bib229","first-page":"1100","article-title":"MicroRNA-21 in Scleroderma fibrosis and its function in TGF-\u03b2-regulated fibrosis-related genes expression","volume":"33","author":"Zhu","year":"2013"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925003619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925003619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T16:06:39Z","timestamp":1750435599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925003619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":229,"alternative-id":["S0014299925003619"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177607","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifibrotic therapeutic strategies in systemic sclerosis: Critical role of the Wnt\/\u03b2-catenin and TGF-\u03b2 signal transduction pathways as potential targets","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177607"}}